1. Home
  2. BTDR vs NUVB Comparison

BTDR vs NUVB Comparison

Compare BTDR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bitdeer Technologies Group

BTDR

Bitdeer Technologies Group

N/A

Current Price

$5.67

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.01

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTDR
NUVB
Founded
2021
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BTDR
NUVB
Price
$5.67
$4.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
13
Target Price
★ $20.92
$12.45
AVG Volume (30 Days)
★ 10.1M
4.9M
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.56
EPS
★ N/A
N/A
Revenue
N/A
★ $62,902,000.00
Revenue This Year
$54.56
$222.99
Revenue Next Year
$70.16
$23.49
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 698.96
52 Week Low
$5.03
$3.98
52 Week High
$20.72
$9.75

Technical Indicators

Market Signals
Indicator
BTDR
NUVB
Relative Strength Index (RSI) 36.09 32.21
Support Level $5.03 N/A
Resistance Level $13.15 $5.06
Average True Range (ATR) 0.73 0.26
MACD 0.05 -0.02
Stochastic Oscillator 19.28 3.87

Price Performance

Historical Comparison
BTDR
NUVB

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: